A new publicly quoted pharmaceutical company backed by Sudocrem founder Dr Ray Stafford is predicting revenues of up to $1.5 billion from one of its drugs, which is used to treat rare genetic skin disorders.
The drug, which is currently going through the approval process, will be used to treat epidermolysis bullosa (EB). In its most severe form, the disease causes infant death, and at its mildest, causes painful and disfiguring blisters through childhood and into...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team